全文获取类型
收费全文 | 1261465篇 |
免费 | 89812篇 |
国内免费 | 3207篇 |
专业分类
耳鼻咽喉 | 16457篇 |
儿科学 | 42609篇 |
妇产科学 | 34424篇 |
基础医学 | 182516篇 |
口腔科学 | 34413篇 |
临床医学 | 111011篇 |
内科学 | 253348篇 |
皮肤病学 | 30418篇 |
神经病学 | 102787篇 |
特种医学 | 46000篇 |
外国民族医学 | 406篇 |
外科学 | 183038篇 |
综合类 | 24991篇 |
一般理论 | 458篇 |
预防医学 | 102448篇 |
眼科学 | 27708篇 |
药学 | 90080篇 |
3篇 | |
中国医学 | 2884篇 |
肿瘤学 | 68485篇 |
出版年
2021年 | 12005篇 |
2019年 | 12528篇 |
2018年 | 18812篇 |
2017年 | 13615篇 |
2016年 | 14801篇 |
2015年 | 16625篇 |
2014年 | 21600篇 |
2013年 | 32952篇 |
2012年 | 46910篇 |
2011年 | 48988篇 |
2010年 | 27908篇 |
2009年 | 25181篇 |
2008年 | 44137篇 |
2007年 | 46763篇 |
2006年 | 46160篇 |
2005年 | 44827篇 |
2004年 | 42973篇 |
2003年 | 40837篇 |
2002年 | 39083篇 |
2001年 | 53497篇 |
2000年 | 54725篇 |
1999年 | 46116篇 |
1998年 | 12663篇 |
1997年 | 11253篇 |
1996年 | 11187篇 |
1995年 | 10715篇 |
1994年 | 9883篇 |
1993年 | 9206篇 |
1992年 | 35429篇 |
1991年 | 34360篇 |
1990年 | 33738篇 |
1989年 | 32301篇 |
1988年 | 29480篇 |
1987年 | 29503篇 |
1986年 | 27558篇 |
1985年 | 26521篇 |
1984年 | 19800篇 |
1983年 | 16672篇 |
1982年 | 10005篇 |
1979年 | 18103篇 |
1978年 | 13089篇 |
1977年 | 11101篇 |
1976年 | 10445篇 |
1975年 | 11032篇 |
1974年 | 13374篇 |
1973年 | 12892篇 |
1972年 | 11867篇 |
1971年 | 11083篇 |
1970年 | 10334篇 |
1969年 | 9704篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
981.
Andreas Lange Claudia Kistler Tanja B. Jutzi Alexandr V. Bazhin Claus Detlev Klemke Dirk Schadendorf Stefan B. Eichmüller 《Experimental dermatology》2009,18(6):527-535
Abstract: The identification of tumor-specific proteins located at the plasma membrane is hampered by numerous methodological pitfalls many of which are associated with the post-translational modification of such proteins. Here, we present a new combination of detergent fractionation of cells and of subtractive suppression hybridization (SSH) to gain overexpressed genes coding for membrane-associated or secreted proteins. Fractionation of subcellular components by digitonin allowed sequestering mRNA of the rough Endoplasmatic reticulum and thereby increasing the percentage of sequences coding for membrane-bound proteins. Fractionated mRNAs from the cutaneous T-cell lymphoma (CTCL) cell line HuT78 and from normal peripheral blood monocytes were used for SSH leading to the enrichment of sequences overexpressed in the tumor cells. We identified some 21 overexpressed genes, among them are GPR137B, FAM62A, NOMO1, HSP90, SLIT1, IBP2, CLIF, IRAK and ARC. mRNA expression was tested for selected genes in CTCL cell lines, skin specimens and peripheral blood samples from CTCL patients and healthy donors. Several of the detected sequences are clearly related to cancer, but have not yet been associated with CTCL. qPCR confirmed an enrichment of these mRNAs in the rough endoplasmic reticulum fraction. RT-PCR confirmed the expression of these genes in skin specimens and peripheral blood of CTCL patients. Western blotting verified protein expression of HSP90 and IBP2 in HuT78. GPR137B could be detected by immunohistology in HuT78 and in keratinocytes of dysplastic epidermis, but also in sweat glands of healthy skin. In summary, we developed a new technique, which allows identifying overexpressed genes coding preferentially for membrane-associated proteins. 相似文献
982.
983.
Psoriasis is a chronic inflammatory condition that often requires life-long treatment. Conventional therapies have not fully met the needs of psoriatic patients, because of limited efficacy, adverse effects with cumulative use, and patient inconvenience. In the past decade, biologic immunotherapies have become accepted treatments for psoriasis as a result of perceived efficacy and safety on the part of patients and practitioners. However, most data on these medications come from relatively limited short-term trials. In this review, we will focus on the available long-term data on the efficacy of the biologic agents. We will emphasize the strengths and weakness of the available data of the biologic agents that are Food and Drug Administration (FDA)-approved for the treatment of moderate to severe psoriasis (alefacept, efalizumab, * etanercept, infliximab, and adalimumab), with the inclusion of a newer agent currently under FDA evaluation (ustekinumab). 相似文献
984.
Beta2-Microglobulin 总被引:1,自引:0,他引:1
Among the uremic toxins in the "middle molecule" range, beta2-microglobulin (β2-M) is certainly one of the most frequently studied compounds. Its serum level increases with the progression of chronic kidney disease, to reach very high concentrations in patients with end-stage kidney disease. It is the major protein component of dialysis-related amyloidosis, a dramatic complication which results from high extracellular concentration and posttranslational modification of β2-M and a number of other promoters of amyloid fibril formation and deposition in osteo-articular tissues. Effective removal of β2-M can be achieved with highly effective hemodialysis and hemodiafiltration techniques but predialysis session serum levels cannot be normalized. The prevalence and severity of β2-M amyloidosis appear to have decreased in the last 20 years, although its occurrence may simply be delayed. 相似文献
985.
986.
The psychology behind doping in sport 总被引:1,自引:0,他引:1
Drugs and methods to improve physical performance among athletes have been used since the beginning of sport history, but the use of performance enhancing drugs has not always been regarded as cheating. In short, the motives for doping are improving and maintaining physical functioning, coping with the social/psychological pressures and striving for social and psychological goals, including economic benefits. Factors such as, “doping dilemma”, “win at all costs”, cost versus benefit, and the specificity of some specific doping agents, also play major roles. It seems that action on the athletes′ attitude about the achievement of physical improvement and creating effective methods to reveal the drug abuse, are two main ways in winning the struggle against doping. 相似文献
987.
988.
989.